These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36067)

  • 21. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy of ginger with various antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME
    Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective study of promethazine and its failure to produce the expected incidence of sedation during space flight.
    Bagian JP; Ward DF
    J Clin Pharmacol; 1994 Jun; 34(6):649-51. PubMed ID: 9766972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing space motion sickness.
    Jennings RT
    J Vestib Res; 1998; 8(1):67-70. PubMed ID: 9416592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head movements in low and high gravitoinertial force environments elicit motion sickness: implications for space motion sickness.
    Lackner JR; Graybiel A
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A212-7. PubMed ID: 3675494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
    Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G
    Acta Astronaut; 1982; 9(6-7):375-83. PubMed ID: 11541691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of the preparation Gavinton in preventing motion sickness].
    Bodo D; Kotovskaia AR; Galle RR; Gavrilova LN; Gusakova GA
    Kosm Biol Aviakosm Med; 1982; 16(3):49-51. PubMed ID: 7098411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High dose ondansetron for reducing motion sickness in highly susceptible subjects.
    Muth ER; Elkins AN
    Aviat Space Environ Med; 2007 Jul; 78(7):686-92. PubMed ID: 17679566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motion sickness: acquisition and retention of adaptation effects compared in three motion environments.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1983 Apr; 54(4):307-11. PubMed ID: 6847566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical use by U.S. astronauts on space shuttle missions.
    Putcha L; Berens KL; Marshburn TH; Ortega HJ; Billica RD
    Aviat Space Environ Med; 1999 Jul; 70(7):705-8. PubMed ID: 10417009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [These vestibular problems in the absence of gravity...].
    Timsit C
    Ann Otolaryngol Chir Cervicofac; 1986; 103(4):235-43. PubMed ID: 3490819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Space motion sickness during 24 flights of the space shuttle.
    Davis JR; Vanderploeg JM; Santy PA; Jennings RT; Stewart DF
    Aviat Space Environ Med; 1988 Dec; 59(12):1185-9. PubMed ID: 3240221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness.
    Kohl RL; Calkins DS; Mandell AJ
    Aviat Space Environ Med; 1986 Feb; 57(2):137-43. PubMed ID: 3513752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.